8-K: Odyssey Health Secures $173K in Highly Dilutive Debt, Equity

Odyssey Health, Inc. has entered into a securities purchase agreement with Mast Hill Fund, L.P. for a $220,000 promissory note and warrants, yielding $173,000 in net proceeds for business development and working capital.

Summary

• Secured a $220,000 face value, one-year, 10% promissory note and a five-year warrant to purchase 1,000,000 shares of common stock at $0.10 per share from Mast Hill Fund, L.P.
• Net proceeds from the transaction, after an original discount of $22,000 and other fees and expenses, amounted to $173,000.
• The promissory note is convertible into common stock at 85% of the lowest volume-weighted average price (VWAP) during the ten trading days immediately preceding the respective conversion date.
• The company is restricted from certain future financing activities, including Variable Rate Transactions, and faces penalties for various breaches, including failure to maintain public information status or timely deliver shares upon conversion.
• The agreement includes a "Most Favored Nation" clause, requiring the company to offer Mast Hill any more favorable terms granted to other investors in future financings.
• A "Repayment from Proceeds" clause allows Mast Hill to demand repayment of up to 50% of cash proceeds from various sources, including future equity or debt issuances.

Sentiment

Score: 2

Explanation: The financing provides much-needed capital but comes with extremely onerous and dilutive terms, including a high interest rate, a deeply discounted conversion price, restrictive covenants on future financing, and a 'Repayment from Proceeds' clause that severely limits financial flexibility. These terms strongly favor the investor and indicate significant financial distress or a weak bargaining position for the company, posing substantial risks to existing shareholders.

Positives

• Secured $173,000 in net proceeds, providing capital for business development and working capital.
• The financing helps address immediate capital needs for the company's operations.

Negatives

• The promissory note carries a high 10% annual interest rate, escalating to 16% per annum upon default.
• The conversion price for the note is set at a significant discount (85% of the lowest VWAP over 10 trading days), leading to substantial potential dilution for existing shareholders.
• The warrant allows Mast Hill to acquire an additional 1,000,000 shares at a low exercise price of $0.10, further contributing to potential dilution.
• The "Repayment from Proceeds" clause allows the investor to demand up to 50% of future cash proceeds from various sources, including equity or debt issuances, which could severely hinder future growth or capital raising efforts.
• The "Most Favored Nation" clause restricts the company's flexibility in negotiating terms for future financings.
• The agreement includes a confession of judgment provision, allowing the holder to obtain a judgment against the company without further notice upon default.
• The company is prohibited from entering into "Variable Rate Transactions" (e.g., equity lines of credit with floating conversion prices), limiting future financing options.

Risks

• Significant Dilution Risk: The conversion terms of the promissory note (85% of lowest VWAP) and the warrants (1,000,000 shares at $0.10) pose a substantial risk of dilution to existing common stock shareholders.
• High Cost of Capital: The 10% interest rate on the note, escalating to 16% upon default, represents a high cost of capital for the company.
• Operational Restrictions: Covenants restrict the company from changing the nature of its business, selling material assets outside the ordinary course, or entering into Variable Rate Transactions without the investor's consent.
• Future Capital Constraints: The "Repayment from Proceeds" clause, allowing the investor to claim up to 50% of future cash proceeds, could severely limit the company's ability to retain capital for growth or repay other obligations.
• Legal and Enforcement Risks: The confession of judgment provision and various default clauses (e.g., failure to timely deliver shares, public information failures, 3(a)(9)/3(a)(10) transactions) expose the company to immediate and potentially severe legal consequences and penalties.
• Market and Listing Risks: Events of default include delisting, suspension, or failure to be quoted on a Principal Market, which could further impair liquidity and investor confidence.
• Going Concern Risk: While the company's financial statements assume a going concern, the restrictive and dilutive nature of this financing, coupled with the need for capital, suggests underlying financial challenges.

Future Outlook

The company intends to use the net proceeds of $173,000 for business development and general working capital. However, the financing agreement imposes significant restrictions on future capital raising activities, including a prohibition on Variable Rate Transactions, and allows the investor to demand repayment from future cash proceeds, which could constrain the company's financial flexibility and growth prospects.

Management Comments

• Joseph Michael Redmond, Chief Executive Officer, signed the Form 8-K and the financing agreements on behalf of Odyssey Health, Inc.
• The company acknowledges and understands the potentially dilutive effect of the Conversion Shares and Exercise Shares on the Common Stock.
• The company acknowledges that its obligation to issue shares upon conversion/exercise is absolute and unconditional, regardless of dilutive effect.

Industry Context

This financing arrangement reflects a common challenge for smaller, publicly traded companies, particularly those on OTC markets, in securing capital. The highly dilutive terms, restrictive covenants, and high interest rates are often characteristic of financing obtained from institutional investors like Mast Hill Fund, L.P. when traditional bank financing or more favorable equity markets are unavailable. Such terms can significantly impact shareholder value and future operational flexibility, distinguishing the company's capital structure from more mature, larger-cap industry peers with access to broader and less onerous financing options.

Comparison to Industry Standards

• The 10% annual interest rate on the promissory note is significantly higher than typical corporate debt for established companies, which might range from 3-7% depending on credit rating and market conditions. For example, a company with a strong balance sheet might secure a revolving credit facility at SOFR + 200-300 basis points (e.g., 7-8% currently), whereas this rate is indicative of higher perceived risk.
• The conversion price of 85% of the lowest VWAP over 10 trading days is a highly dilutive structure, often seen in distressed or micro-cap financings. More standard convertible notes for growth companies might have a conversion premium (e.g., 20-30% above current market price) or a fixed conversion price, rather than a floating discount to a low-point VWAP.
• The inclusion of a "confession of judgment" provision is an aggressive creditor protection mechanism, rarely seen in financing agreements with larger, more stable public companies, and highlights the investor's demand for strong legal recourse.
• The "Repayment from Proceeds" clause, allowing the investor to claim up to 50% of future cash proceeds from various sources, is an unusually restrictive covenant. This is far more stringent than typical debt covenants that might require a percentage of free cash flow or asset sale proceeds to repay debt, but usually not a broad claim on all cash inflows, including future equity raises.
• The prohibition on "Variable Rate Transactions" limits the company's ability to use common financing tools like equity lines of credit, which, while often dilutive, are sometimes necessary for small companies to access capital over time. This restriction is a direct response to the investor's desire to avoid further dilution from other sources that could impact their own conversion value.

Corporate Governance

Legal Proceedings

• The promissory note includes an affidavit of confession of judgment provision, allowing the holder to obtain a judgment against the company without further notice upon default.
• The company agrees to indemnify and hold harmless the investor for losses arising from breaches of representations, warranties, or covenants, or third-party claims related to the transaction.

Stakeholder Impact

• Shareholders: Existing shareholders face significant potential dilution from the conversion of the promissory note at a discounted price and the exercise of warrants. The restrictive covenants and "Repayment from Proceeds" clause could also limit future growth and shareholder value.
• Creditors: The promissory note has priority over all unsecured indebtedness, potentially impacting the recovery prospects of other unsecured creditors. The confession of judgment provision provides strong recourse for Mast Hill Fund, L.P.
• Management/Employees: The financing provides working capital, which could support ongoing operations and job security in the short term. However, the restrictive covenants and financial penalties for non-compliance add pressure on management.

Next Steps

• Odyssey Health, Inc. will use the $173,000 net proceeds for business development and working capital.
• The company must maintain its listing and trading of its Common Stock on the Principal Market and comply with all reporting obligations under the 1934 Act.
• The company is required to purchase director and officer insurance within 60 calendar days of the closing date, with two years of tail coverage.
• The company must reserve a sufficient number of shares of common stock for the conversion of the note and exercise of the warrants.
• The company must provide Mast Hill Fund, L.P. with piggy-back registration rights for the conversion and exercise shares.

Key Dates

Recommendation

The terms of this financing agreement are exceptionally unfavorable for existing shareholders, indicating a company in a precarious financial position. The deeply discounted conversion price (85% of lowest VWAP), high interest rate (10% escalating to 16%), and the issuance of substantial warrants will lead to severe dilution. Furthermore, the 'Repayment from Proceeds' clause, which allows the investor to claim up to 50% of future cash inflows, severely cripples the company's ability to fund operations, invest in growth, or raise capital from other sources on reasonable terms. The 'Most Favored Nation' clause and prohibition on 'Variable Rate Transactions' further restrict future financial flexibility. The inclusion of a confession of judgment provision underscores the high risk perceived by the investor and the limited bargaining power of the company. These terms suggest that the company is likely to face ongoing financial challenges and that shareholder value will be significantly eroded.

Keywords

Odyssey Health, Mast Hill Fund, Promissory Note, Warrant, Debt Financing, Equity Financing, Dilution, SEC Filing, 8-K, Capital Raise, Corporate Governance, Risk Management, Convertible Debt, OTC Markets